VISIONBLUE Drug Patent Profile

Which patents cover Visionblue, and what generic alternatives are available?

Visionblue is a drug marketed by Dorc and is included in one NDA.

The generic ingredient in VISIONBLUE is trypan blue. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the trypan blue profile page.

Summary for VISIONBLUE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	42
Patent Applications:	710
What excipients (inactive ingredients) are in VISIONBLUE?	VISIONBLUE excipients list
DailyMed Link:	VISIONBLUE at DailyMed

Pharmacology for VISIONBLUE

Drug Class	Diagnostic Dye
Mechanism of Action	Dyes

US Patents and Regulatory Information for VISIONBLUE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dorc	VISIONBLUE	trypan blue	SOLUTION;OPHTHALMIC	021670-001	Dec 16, 2004		RX	Yes	Yes

Expired US Patents for VISIONBLUE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Dorc	VISIONBLUE	trypan blue	SOLUTION;OPHTHALMIC	021670-001	Dec 16, 2004
Dorc	VISIONBLUE	trypan blue	SOLUTION;OPHTHALMIC	021670-001	Dec 16, 2004

International Patents for VISIONBLUE

See the table below for patents covering VISIONBLUE around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	232400
Austria	234118
Australia	2003208122
Australia	3853699
Australia	3853799

Last updated: July 5, 2026

VisionBlue (VISIONBLUE) market dynamics and financial trajectory: sales outlook, exclusivity-driven competition, and patent/regulatory-driven risk

VisionBlue’s market and financial trajectory cannot be analyzed from the information provided. No drug composition, strength, route, NDA/BLA number, manufacturer, launch date, FDA status, ORANGE BOOK listings, payer/reimbursement coverage, or disclosed sales figures are present, and without those inputs it is not possible to produce a complete, accurate market-dynamics and IP-exclusivity competitor-risk assessment.

What is VISIONBLUE’s FDA status and who markets it?

Featured snippet answer: Cannot be determined from provided data.

What FDA pathway does VisionBlue use (NDA vs ANDA vs 505(b)(2))

No FDA pathway details are provided.

Is VisionBlue listed in the Orange Book

No Orange Book listing data (NDA number, active ingredient, patent numbers, expiration dates) is provided.

Does VisionBlue have REMS, labeling limits, or distribution controls

No REMS or distribution constraints are provided.

How has VISIONBLUE performed commercially since launch?

Featured snippet answer: Cannot be determined from provided data.

Revenue baseline, growth rate, and geography

No sales/revenue history (US/EU/ROW), quarterly or annual figures, or growth metrics are provided.

Channel mix and contracting structure

No information is provided on wholesaler vs specialty pharmacy, PBM formulary position, rebates, or net price.

Expected time-to-peak and adoption curves

No launch timeline, indication expansion, or prescribing adoption data is provided.

What market dynamics are driving VisionBlue demand?

Featured snippet answer: Cannot be determined from provided data.

Therapeutic category and target population

No indication, mechanism, or patient incidence is provided.

Payer coverage and formulary placement

No coverage or formulary tier data is provided.

Competitive set and substitution behavior

No competitors are identified.

Which competitors threaten VISIONBLUE, and when do exclusivity or patent barriers fall?

Featured snippet answer: Cannot be determined from provided data.

How many patents cover VisionBlue and what are the expiration dates

No patent estate details are provided.

When does VisionBlue lose exclusivity (NCE, patent term adjustment, pediatric exclusivity)

No exclusivity timeline is provided.

What generic or biosimilar entry risks exist

No Paragraph IV filings or biosimilar landscape is provided.

What patent estate protects VISIONBLUE, and how strong is it?

Featured snippet answer: Cannot be determined from provided data.

Method-of-use vs formulation vs composition-of-matter coverage

No patent claims, claim scope, or patent types are provided.

Who owns the key patents and who is licensed

No assignees or licensing facts are provided.

What patent litigation affects VisionBlue

No litigation docket, settlement, or injunction history is provided.

How do patent cliffs and exclusivity windows affect VisionBlue’s pricing power?

Featured snippet answer: Cannot be determined from provided data.

Net price behavior around approval and launch

No net pricing history is provided.

Generic discounting and formulary switching scenarios

No competitor or expected entrant strategy is provided.

Manufacturer incentives and rebate pressure ahead of entry

No payer contracting data is provided.

What is the Orange Book status of VISIONBLUE?

Featured snippet answer: Cannot be determined from provided data.

Which patents are listed by NDA number

No NDA number or patent list is provided.

How many patents are “listed” versus “associated”

No listing detail is provided.

What is the latest relevant listed expiration date

No expiration data is provided.

What is the Paragraph IV and settlement landscape for VISIONBLUE?

Featured snippet answer: Cannot be determined from provided data.

Have any ANDA filers challenged patents

No Paragraph IV facts are provided.

Was there a 30-month stay and did it end

No timeline is provided.

Were settlements reached

No settlement details are provided.

How does VISIONBLUE compare with branded and generic alternatives?

Featured snippet answer: Cannot be determined from provided data.

Efficacy, dosing frequency, and administration route

No clinical or dosing details are provided.

Safety profile and label breadth

No adverse events or labeling differences are provided.

Real-world utilization and persistence

No claims-based utilization metrics are provided.

What manufacturing or IP barriers could limit generic entry for VISIONBLUE?

Featured snippet answer: Cannot be determined from provided data.

Process patents and supply constraints

No manufacturing details are provided.

Complex delivery systems and formulation switching

No dosage form or formulation complexity is provided.

Substitution constraints under pharmacy benefit designs

No PBM switching rules are provided.

Key Takeaways

• Market-dynamics and financial trajectory for VisionBlue cannot be produced from the information provided.
• No FDA, Orange Book, patent, litigation, pricing, or sales data is present to quantify exclusivity-driven risk or competitive entry timing.
• No basis exists to model revenue exposure, patent-cliff behavior, or generics risk for VisionBlue.

FAQs

1. What is VisionBlue’s NDA number and listed active ingredient?
2. Is VisionBlue eligible for patent term adjustment or pediatric exclusivity?
3. Are there any ANDA Paragraph IV challenges for VisionBlue?
4. What are the key listed patents for VisionBlue in the Orange Book and their expiration dates?
5. Who is the manufacturer and what is the latest reported net sales trend for VisionBlue?

References

1. (No sources were cited because no drug-identifying or regulatory data was provided.)